Although there are still safety issues concerning PDE5 inhibitor use in patients with coronary artery disease, recent studies have shown that the use of PDE5 inhibitors, even in a post-MI cohort, reduced mortality and HF hospitalizations8. The gene discussed is PDE5A; the disease is coronary artery disorder.